Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. This 26-week, phase 2a, randomized, double-blind, PBO-controlled, mult...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes care 2017-05, Vol.40 (5), p.632-639
Hauptverfasser:	Hollander, Priscilla, Bays, Harold E, Rosenstock, Julio, Frustaci, Mary Ellen, Fung, Albert, Vercruysse, Frank, Erondu, Ngozi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antidiabetics Appetite Depressants - administration & dosage Appetite Depressants - adverse effects Blood pressure Blood Pressure - drug effects Body mass Body mass index Body weight Body weight loss Canagliflozin - administration & dosage Canagliflozin - adverse effects Clinical trials Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 Double-Blind Method Dyslipidemia Evidence-based medicine Female Humans Hypertension Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Male Middle Aged Obesity Obesity - complications Obesity - drug therapy Obesity - physiopathology Overweight Overweight - complications Overweight - drug therapy Overweight - physiopathology Phentermine - administration & dosage Phentermine - adverse effects Research design Safety Thiophenes - therapeutic use Weight control Weight loss Weight reduction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To assess the efficacy and safety of coadministration of canagliflozin (CANA) and phentermine (PHEN) compared with placebo (PBO) and CANA or PHEN monotherapies in individuals who were overweight and obese without type 2 diabetes. This 26-week, phase 2a, randomized, double-blind, PBO-controlled, multicenter, parallel-group study enrolled individuals who were obese or overweight without type 2 diabetes ( = 335, aged 18-65 years, BMI ≥30 to
ISSN:	0149-5992 1935-5548
DOI:	10.2337/dc16-2427